In addition, inhibiting the CAMK2/CREB1 pathway resensitized MDR ovarian cancer cells to not only doxorubicin but also paclitaxel and topotecan, which are clinically employed to treat ovarian cancer (48). This evidence concerns the gene CAMK2B and ovarian cancer.